The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

被引：0
|
作者：
Liu, Yang [1 ]
Zhao, Shuangtao [2 ]
Jiang, Changying [1 ]
Yao, Yixin [1 ]
Murfin, Kelley Paige [1 ]
Grundman, Hadley [1 ]
Zhang, Liang [1 ]
Nomie, Krystle [1 ]
Wang, Linghua [2 ]
Wang, Michael [1 ,3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131079
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1487
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
    Lan Pham
    Zhang, Liang
    Tao, Wenjing
    Zhao, Donglu
    Zhang, Hui
    Xie, Jingmeng
    Wang, Jack
    Nomie, Krystle
    Wang, Michael
    BLOOD, 2015, 126 (23)
  • [2] Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
    Zhang, Liang
    Guo, Hui
    Zhang, Hui
    Yao, Yixin
    Liu, Yang
    Zhang, Shaojun
    Rui, Lixin
    Wang, Linghua
    Nomie, Krystle
    Wang, Michael L.
    BLOOD, 2019, 134
  • [3] Statins in Combination with Ibrutinib bypasses Resistance to Ibrutinib in Mantle Cell Lymphoma
    Al-Zebeeby, Aoula
    Abbas, Ali
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 193 - 196
  • [4] Overcoming Mantle Cell Lymphoma's Ibrutinib Resistance
    Sinha, Gunjan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11):
  • [5] Overcoming primary ibrutinib resistance in mantle cell lymphoma
    Zhang, Leo
    Lan Pham
    Zhang, Hui
    Xie, Jingmeng
    Tao, Wenjing
    Bell, Taylor
    Chen, Zhihong
    Nomie, Krystle
    Fang, Bingliang
    Wang, Michael
    CANCER RESEARCH, 2016, 76
  • [6] Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma
    Hoang, Nguyet-Minh
    Liu, Yunxia
    Bates, Paul D.
    Heaton, Alexa R.
    Lopez, Angelica F.
    Liu, Peng
    Zhu, Fen
    Chen, Ruoyu
    Kondapelli, Apoorv
    Zhang, Xiyu
    Selberg, Paul E.
    Ngo, Vu N.
    Skala, Melissa C.
    Capitini, Christian M.
    Rui, Lixin
    CELL REPORTS MEDICINE, 2024, 5 (04)
  • [7] Ibrutinib for mantle cell lymphoma
    Tucker, David L.
    Rule, Simon A.
    FUTURE ONCOLOGY, 2016, 12 (04) : 477 - 491
  • [8] Molecular Pathways Associated with Ibrutinib Resistance in Mantle Cell Lymphoma
    Zhang, Liang
    Nomie, Krystle
    Zhang, Shaojun
    Liu, Yang
    Guo, Hui
    Huang, Shengjian
    Wang, Jeffrey
    Lopez, Elyse
    Zhang, Hui
    Lorence, Elizabeth A.
    Merolle, Maria
    Balaji, Swathi
    Ahmed, Makhdum
    Jiang, Changying
    Wang, Linghua
    Wang, Michael
    BLOOD, 2017, 130
  • [9] Pirtobrutinib Overcomes Ibrutinib and Venetoclax Resistance in Mantle Cell Lymphoma
    Liu, Yang
    Jiang, Changying
    Yan, Fangfang
    McIntos, Joseph
    Jordan, Alexa A.
    Li, Yijing
    Che, Yuxuan
    Cai, Qingsong
    Wang, Wei
    Nie, Lei
    Wang, Michael
    BLOOD, 2021, 138
  • [10] Ibrutinib for the treatment of mantle cell lymphoma
    Shah, Nimish
    Hutchinson, Claire
    Rule, Simon
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 521 - 531
12345